Industry May Like FDA's Biosimilar Guidance Withdrawal, But Not The New Information Vacuum

Sponsors may have to rely even more on the advice they receive from formal meetings as FDA decides to rewrite draft guidance on statistical approaches to evaluate analytical similarity for biosimilars.